Skip to main content

Research Repository

Advanced Search

All Outputs (2)

Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism (2010)
Journal Article
Whittle, A. M., Allsup, D. J., & Bailey, J. R. (2011). Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism. Leukemia Research, 35(3), 419-421. https://doi.org/10.1016/j.leukres.2010.11.011

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in cancer patients. The literature is sparse on the incidence in the most common lymphoid malignancy, chronic lymphocytic leukaemia (CLL). We calculated the incidence rates for... Read More about Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism.

Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells (2010)
Journal Article
Pointon, J. C., Eagle, G., Bailey, J., Evans, P., Allsup, D., & Greenman, J. (2010). Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells. Oncology Reports, 24(5), 1315-1321. https://doi.org/10.3892/or_00000988

Numerous chemotherapeutic regimens exist for the treatment of symptomatic or progressive chronic lymphocytic leukaemia (CLL). However, once the disease becomes refractory to nucleoside-based therapy the prognosis is poor. In this study we investigate... Read More about Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells.